| | Author/year | Survival median | Disease-free survival | Mortality | Morbidity | Hospital stay | Comments |
| | Schipper et al., 2008 [20] | Total P/D 17.2 months
Subtotal P/D 8.1 months | TP, 1 year, 80%; 2 years 35% ST, 1 year, 30%; 2 years, 15%; 3 years, 3.7% | 2.9% | 2 + 2 subtotal (20 + 5.9%) | 6.5 days (median) | Total or subtotal pleurectomy groups | | Luckraz et al., 2010 [21] | 26 months | 55%, 2 years | 1.1% | 13% | unknown | | | Flores et al., 2008 [22] | 23 months | 12% at 5 years | 4% | 6.4% (respiratory only reported) | unknown | | | Okada et al., 2008 [23] | 17 | 24%, 3 years | 0% | unknown | unknown | | | Nakas et al., 2008 [26] | 15.3 R
7.1 NR | 66%, 54%, 33%, and 16.3% at 1, 2, 3, and 4 years; R—45%, 16%, 4%, and 0%, NR | 5.9 R—9.8% NR | 55% R—28% NR | unknown | Unsuitable for EPP | | Aziz et al., 2002 [15] | 14 |
45% at 1 year; 0% at 3 years | 0% | unknown | unknown | | | Martin-Ucar et al., 2001 [27] | 7.2 | 31% at 1 year | 7.8% | 9.8% | 7 | Target was symptom relief | | Lang-Lazdunski et al., 2011 [28] | 24 |
91.7% at 1 year; 61% at 2 years | 0% | 25% | unknown | TMT plus hyperthermic pleural lavage | | Lang-Lazdunski et al., 2012 [24] | 12.8 | 49% at 2 years; 30.1% at 5 years | 0% | 27.7% | unknown | | | Rena and Casadio 2012 [25] | 23 stage II
32 stage I | stage I: two years and 3 years, 67% and 44%
stage II: 49% and 9% | 0% | 24% | 7 | QoL |
|
|
